ADDICTOlogical Intervention in LIVEr Transplantation Recipients
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Jun 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a specialized addiction intervention for patients who have received a liver transplant due to alcohol-related liver disease. The goal is to see if this intervention can help reduce the likelihood of patients returning to alcohol use after their transplant. Research shows that many liver transplant recipients struggle with alcohol relapse, which can seriously affect their long-term health. By integrating an addiction support team into the transplant process, the study aims to better manage alcohol use disorder and improve outcomes for these patients.
To participate in this trial, individuals must be at least 18 years old and have undergone a liver transplant specifically for alcohol-related liver disease. They should be recovering from their surgery and not currently receiving long-term addiction treatment. Participants will be followed for two years to monitor their alcohol use and overall health. This study is important because it could lead to better support and resources for liver transplant recipients, helping them maintain sobriety and improve their quality of life after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 years or above
- • Hospitalized for LT for AALD as primary or secondary indication
- • Discharged from intensive care unit to hepatology or surgery wards
- Exclusion Criteria:
- • Having a longitudinal pre-transplant addiction follow-up defined by at least 3 appointments within the last 6 months or a temporary contraindication to LT due to alcohol consumption while on the waiting list
- • Severe alcohol-associated hepatitis as primary indication for liver transplantation
- • Impossibility of patient follow up over the next 2 years
- * General criteria:
- • Refusal or absence of informed consent,
- • Non-affiliation to the French national health insurance,
- • Persons placed under legal protection, guardianship or curatorship
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, , France
Rennes, , France
Tours, , France
Lille, , France
Toulouse, , France
Montpellier, , France
Bordeaux, , France
Marseille, , France
Strasbourg, , France
Dijon, , France
Lyon, , France
Besançon, , France
Nice, , France
Clermont Ferrand, , France
Paris, , France
Paris, , France
Paris, , France
Patients applied
Trial Officials
Hélène DONNADIEU, MD, PhD
Principal Investigator
University Hospital, Montpellier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported